No Data
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Top Midday Stories: Spirit Airlines Files for Chapter 11 Bankruptcy Protection; Trump Team Looking to Ease Rules for Self-Driving Cars
European Equities Traded in the US as American Depositary Rise in Monday Trading
Novo Nordisk To Offer Wegovy In China At Fraction Of USA Cost
Global Companies With at Least 50% U.S. Revenue Exposure as Trump Eyes Tariffs: BofA
The first prescription of Semaglutide for weight reduction was given to patients with a 15-year history of obesity. Experts remind that weight loss drugs are not suitable for everyone.
According to Yicai, on the second day of the official commercial launch of novo-nordisk A/S's long-term weight management glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide weekly preparation novo-yang in China, the first prescription in a public hospital nationwide was issued at Shanghai Fudan University Zhongshan Hospital Endocrinology Department. Currently, several top-tier hospitals in Shanghai have expressed to reporters that they can prescribe novo-yang, and drug supply is also catching up. However, experts remind that weight loss medications are not suitable for everyone, only patients who meet the criteria can use the medication. The Deputy Director of the Endocrinology Branch of the Chinese Medical Association, Fudan.